PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Gastroenterology. Author manuscript; available in PMC Jun 1, 2012.
Published in final edited form as:
PMCID: PMC3109236
NIHMSID: NIHMS290910
POLYCYSTIC LIVER DISEASES: CONGENITAL DISORDERS OF CHOLANGIOCYTE SIGNALING
Mario Strazzabosco, MD, PhD and Stefan Somlo, MD
Liver Center and Section of Digestive Diseases, Yale University, New Haven, CT
CeLiveR, Center for Liver Research, Bergamo, Italy
Department of Clinical Medicine and Prevention, University of Milano-Bicocca
Departments of Internal Medicine and Genetics, Yale University School of Medicine, New Haven, CT
Reprint requests to: Mario Strazzabosco MD, PhD, Yale Liver Center & Digestive Disease Section, Department of Medicine, Yale University School of Medicine, 333 Cedar Street LMP 1080, 06520 New Haven, CT USA, Phone:+1-203-785-7281, Fax:+1-203-785-7273, mario.strazzabosco/at/yale.edu
Polycystic liver diseases (PLD) are inherited disorders of the biliary epithelium, caused by genetic defects in proteins associated with intracellular organelles, mainly the endoplasmic reticulum and the cilium. PLD are characterized by the formation and progressive enlargement of multiple cysts scattered throughout the liver parenchyma, and include different entities, classified based on their pathology, inheritance pattern, involvement of the kidney and clinical features. PLD should be considered as congenital diseases of cholangiocyte signaling. Here, we will review the changes in signaling pathways involved in liver cyst formation and progression, and their impact on cholangiocyte physiology. Each pathway represents a potential target for therapies aimed at reducing disease progression.
Keywords: Liver cysts, cholangiopathies, gene defects, biliary epithelium, liver transplantation, ADPKD, ARPKD, PCLD
Polycystic liver diseases (PLD) are a genetically and clinically heterogeneous group of inherited cholangiopathies13. Autosomal Dominant Polycystic Kidney Disease (ADPKD) occurs in 1:500-1,000 individuals; it is characterized by the formation of multiple cysts in the kidney, liver and pancreas, and by a variety of vascular abnormalities. Despite extensive cyst substitution of the hepatic parenchyma, liver function is well preserved, portal hypertension is rare, and the patient is asymptomatic, unless complications develop (including compression, cyst infections or bleeding). The “isolated” Polycystic Liver Disease (PCLD) is a far less common disease that shares many clinical features of ADPKD, except for the renal involvement. Fibropolycystic diseases, i.e., Congenital Hepatic Fibrosis (CHF), Caroli disease (CD), and Autosomal Recessive Polycystic Kidney Disease (ARPKD) are also rare diseases, with a prevalence of 1:20,000 live births. CD and CHF are characterized by recurrent acute cholangitis (CD) and severe portal hypertension, due to excessive peribiliary fibrosis (CHF). CD patients have an increased risk of cholangiocarcinoma. Other, rarer disorders associated with PLD, have been reviewed elsewhere4. The clinical approach to PLD has been recently reviewed5. Here we will discuss the pathogenic aspects that are specific to the liver.
ADPKD is associated with mutations in two genes: PKD1, and PKD2, which encode polycystin-1 (PC1) and polycystin-2 (PC2), respectively. PC1, a 460 kDA transmembrane protein, is localized in the primary cilium, plasma membrane and adherens junctions. PC-1 functions as a mechanoceptor that, sensing changes in apical flow, stimulates PC2-mediated Ca2+ signals1. In addition, cleaved fragments of the PC1 cytoplasmic tail, translocate to the nucleus and bind to β-catenin, preventing its transcriptional activity (fragment p200)6, or interact with STAT6/P100 (fragment 112)7, or decrease the ERK-dependent phosphorylation of tuberoussclerosis-2-complex8. PC2 (TRPP2) is a 110-kDA transmembrane protein with both the N- and C-terminus located intracellularly. PC1 and PC2 colocalize in the cilium and physically interact through their C-terminus, however, the largest pool of PC2 is located in the ER9,10. PC2 is a member of the transient receptor potential channels (TRP) family and functions as a non-selective Ca2+channel. TRP channels have the ability to multimerize with other proteins that determine their function1113. Thus, PC2 responds to mechanical stimuli (bending of the cilium) or to biliary osmolarity or participates in receptor-operated Ca2+-signaling, depending on its interactions with PC1, TRVP4, or IP3R9,10. PC2 also interacts with the two major intracellular Ca2+channels (i.e. ryanodine receptors–RyR- and inositol,1,4,5-trisphosphate receptors–IP3R) and regulates cytoplasmic and ER-Ca2+ homeostasis9,10.
PRKCSH and SEC63, the genes responsible for PCLD14,15, encode for proteins expressed in the ER that are associated with the processing of glycoproteins in the endoplasmic reticulum (ER). PRKCSH, encodes for the protein kinase-C-substrate 80K-H (or hepatocystin), a protein that regulates the correct localization in the ER, of enzymes involved in the quality control of newly synthesized glycoproteins15. The SEC63 gene encodes for a component of the molecular machinery regulating translocation and folding of newly synthesized membrane glycoproteins14.
Mutations in the PKHD1 gene cause ARPKD, CD and CHF1. PKHD1 encodes for fibrocystin, a large protein with a single transmembrane domain, and sequence homologies with plexins and the HGF receptor (C-Met). Fibrocystin is localized in primary cilia and basal bodies of several epithelia. Fibrocystin complexes with PC2, and is involved in cell Ca2+ homeostasis; fibrocystin can also signal via the proteolytic cleavage of its C-terminus16,17. A variety of functions have been proposed for fibrocystin, from proliferation to secretion, terminal differentiation, tubulogenesis18. Transcription of PKHD1is regulated by HNF-1β a transcription factor expressed in cholangiocyte19.
In ADPKD and PCLD, liver cysts are scattered throughout the parenchyma, without connection to the biliary tree, that appears anatomically intact and without accompanying fibrosis. By contrast, in fibropolycystic diseases, liver cysts are connected to the biliary tree, which appear distorted and embedded in abundant fibrotic tissue. Cyst formation is not a common reaction of the biliary epithelium to liver damage. In response to obstructive cholestasis, the biliary epithelium generates multiple branching tubules, whereas in inflammatory processes, reactive cholangiocytes form a ramified mesh with cellular chords that do not encircle a lumen. Mice with conditional PC knock-out show a progressive formation of liver cysts, even when the induction is performed weeks after birth20,21. This indicates that polycystins are necessary to maintain a normal biliary architecture during adult life. It is not clear whether the lack of polycystin expression induces pathologic changes throughout the biliary tree, or only in specialized portions that maintain “developmental” capabilities. The pathogenic sequence leading to liver cyst formation and progressive growth is the subject of extensive investigation.
Altered biliary developmental program (Ductal plate malformation)
The biliary tree is a branching system of tubules that begins at the canals of Hering, and then converges to create ducts of progressively larger size. Biliary ontogenesis begins when periportal hepatoblasts surrounding branches of the portal vein, undergo a phenotypic switch and assemble into a layer of epithelial cells, called “ductal plate”3,22. Over the following weeks, specific segments of the ductal plate form a second layer of cells, which eventually arranges into tubular structures that mature and become incorporated into the mesenchyme of the developing portal space. Non-duplicated ductal plates are then reabsorbed by apoptosis (ductal plate remodeling). PLD are characterized by macroscopic cysts and by the presence of multiple biliary microhamartomas, scattered throughout the liver parenchyma. Both structures resemble ductal plates that failed to remodel, justifying the inclusion of PLD among the ductal plate malformations (DPM3,22).
Cilia and beyond
Primary cilia are involved in the regulation of fundamental biological activities of epithelial cells, including differentiation, proliferation and secretion. Several proteins encoded by genes associated with PLD are expressed in primary cilia; DPM is consistently observed in mice defective for ciliary proteins. Cholangiocyte primary cilia are non-motile, but can bend in response to changes in luminal fluid flow and transduce a mechanical force into an intracellular calcium signal. Changes in luminal flow increased [Ca2+]i and cAMP production, an effect inhibited by silencing PC1, PC2, or adenylyl-cyclases-6 (AC6)2,23. By contrast proteins associated with PLD, are not exclusively expressed in cilia. For example, PC2 is also highly expressed in the ER, where it regulates calcium levels9,13. Furthermore, hepatocystin and SEC63 (PCLD) are expressed in the ER, and yet, the clinical presentation is similar14.
Altered epithelial fluid secretion
Cholangiocytes possess secretory properties and actively contribute to bile formation, thereby regulating its volume, pH and composition24. The net amount of fluid secreted is the end-result of several pro-secretory and anti-secretory stimuli. Autocrine, paracrine and endocrine stimuli are integrated at the level of adenyl cyclases (ACs)25, the enzymes that synthesize the second messenger cAMP. CFTR, a cAMP/PKA-activated Cl channel, is the main regulator of bile secretion. CFTR stimulates Cl and HCO3 efflux, inhibits NHE3 dependent Na+ absorption and facilitates apical release of ATP and purinergic receptors activation24. Of note, the severity of ADPKD was milder in two cases in which ADPKD coexisted with cystic fibrosis, a disease that impairs CFTR-dependent Cl secretion26. However, fluid secretion is not the major pathophysiologic mechanisms leading to cyst growth in the liver. To account for the very slow growth rates of the cysts, the net difference between absorption and secretion should be very subtle and constant in the face of increasing intraluminal pressure. However, the increased intraluminal pressure may stretch the lining epithelial cells and induce cell proliferation, via apical secretion of purinergic agonists, and their interaction with P2X and P2Y purinergic receptors.
Increased cholangiocyte proliferation
The cystic epithelium has a very high mitotic index (as judged by PCNA and Ki67 expression)20,21, suggesting that increased proliferation of cystic cholangiocytes is the major determinant of cyst growth. Markers of proliferation and apoptosis are both present in liver cysts, however, the size of the liver progressively increases (about 2% of the liver volume per year), indicating that apoptosis does not match proliferation.
During cell division, the epithelial cells of a tubular structure must align their mitotic spindle in such a way that the daughter cells will grow along the longitudinal, rather than the horizontal, axis. The ability to organize cell division and the growth of the epithelial layer along a specific plane (“planar cell polarity”) is an important property of epithelia, regulated by the non-canonical Wnt pathway; its malfunction may result in tubule enlargement rather than tubule elongation. In rodent models with fibrocystin (Pkhd1) deficiency, the orientation of the mitotic spindle of kidney cells is distorted27. Direct experimental evidence for this model in ADPKD and in cholangiocytes is yet to be produced.
Cystic fluid and conditioned medium of cultured cystic cholangiocytes contain elevated levels of cytokines and growth factors, which are able to promote cell proliferation and cyst expansion. Among them, IL-6, EGF, VEGF and IGF-128,29 utilize autocrine loops to stimulate the proliferation of cystic cholangiocytes. Their expression likely represents the phenotypic and functional signature of a relative loss of cell differentiation. For example, the pattern of angiogenic factor expression by cystic cholangiocytes in ADPKD is similar to that of the ductal plates30.
Estrogens31 and VEGF21,28 promote cyst growth via ERK1/2, which is the main pathway of regulation of cholangiocyte proliferation, whereas the PI3-kinase/AKT/mTOR pathway is activated by IGF1 in ADPKD liver cysts20. In cholangiocytes, cAMP/PKA activates Ras and ERK1/2 and cell proliferation, an effect that is significantly increased in cystic cholangiocytes. This is a major difference with kidney cells in which cAMP inhibits replication in normal condition, but stimulates replication if polycystin are defective. The reason for these differences may lay in the differential sensibility to cAMP of cells-specific B-Ras and C-Ras isoforms.
Autocrine and paracrine angiogenic signaling
Ductal plate malformations are frequently associated with an abnormal vascular morphology, thereby resulting from increased angiogenic signaling between bile ducts and liver vascular structures. The anatomic relationship between intrahepatic bile ducts and hepatic arterial vascularisation begins during the developmental stages and is mediated by VEGF released by maturing bile ducts30. Cystic cholangiocytes overexpress VEGF, angiopoietin-1 and their cognate receptors VEGFR2 and Tie-2. VEGF and angiopoietin-1 stimulate cholangiocyte proliferation and the formation of vessels around the growing cysts28. VEGF production is controlled by Hypoxia-Inducible Factor-1α (HIF-1). Cystic cholangiocytes express more HIF-1α than normal cholangiocytes, when cultured under the same conditions, indicating expression of VEGF/HIF-1α is caused by the loss of PC1 and PC2 function, rather than by hypoxia of the cystic epithelium21. HIF-1α levels can be modulated in normoxic conditions by a number of factors, (including IL-1, IL-6, EGF, HGF, TGFβ, 17-β-estradiol, IGF-1)29, which can stabilize or phosphorylate HIF-1α via PI3K/AKT/tuberin/mTOR or Raf/MEK/ERK, or STAT3. Inhibition of VEGF production or blockage of VEGF-R2 in vivo in PC2 defective mice inhibits cyst growth21.
Extracellular matrix (ECM) remodeling
Remodeling of the ECM is necessary for the expansion of the cyst wall. Matrix metalloproteinases (MMPs) are involved in the breakdown of extracellular matrix in embryonic development as well as in tissue repair and remodeling. IL-8, a cytokine known to be up-regulated in the liver cyst epithelium, stimulates MMP2 and MMP9 production by endothelial cells and portal myofibroblasts. MMP2 is increased in polycystic kidneys and participate to the ECM remodeling necessary to accommodate cyst expansion29. On the contrary, a major feature of ARPKD/CHF/CD, is the progressive establishment of fibrosis in the hepatic portal space in close vicinity to aberrant bile ducts. The mechanisms of fibrogenesis in fibropolycystic diseases are not clear.
There is convincing evidence that PLD are disorders of intracellular signaling; altered Ca2+ homeostasis, and increased production of cAMP being the main defects. Lower intracellular Ca2+ and higher cAMP levels have been consistently reported in cystic epithelia from ADPKD and ARPKD models10, 23. The mechanistic relationship between defective polycystins/fibrocystin and the disorder of these second messengers is unclear. Here, we will provide a reasonable, but yet speculative, working model based on experimental evidence generated in ADPKD models (Fig1). It is important to emphasize that the fine molecular tuning of these interactions remains largely unknown.
fig. 1
fig. 1
Alterations of intracellular signaling in PLD. See text for details.
Several studies, including our own observations in cystic cholangiocytes, indicate that intracellular Ca2+ levels are lower in the cystic epithelium (below 100 nM)10,23. PC2 functions as a membrane Ca2+ channel, in response to mechanical stimulations (in partnership with PC1) or to variations in osmolarity (in partnership with TRVP4)32. PC-2 also interacts both physically and functionally with IP3R and RyR, thereby regulating Ca2+ homeostasis in the ER9,10, the largest controllable intracellular Ca2+ store in non-excitable cells. Thus, a defect in PC-2 may affect resting [Ca2+] by reducing extracellular Ca2+ entry and by altering ER Ca2+ homeostasis.
The amount of cAMP produced by a given cell is the result of the activity of several adenylyl cyclase (AC) isoforms, which respond to different stimuli and second messengers. At least seven of them are expressed in cholangiocytes25. Among them, AC8 is regulated by Ca2+/calmodulin, while AC5 and AC6 are inhibited at physiological Ca2+ concentrations (100 to 200 nM), but can be activated at the Ca2+ concentrations measured in polycystin-defective cells. Thus, at the [Ca2+]i measured in cystic cholangiocytes, AC6 becomes more prone to activation than AC8. Of note, AC6 gene silencing abolishes shear stress-induced signaling in polarized cholangiocytes23.
Thus, the increased cAMP level in cystic epithelia may be related to the activation of AC6, facilitated by the changes in intracellular Ca2+ homeostasis. Increased epithelial levels of cAMP stimulate fluid secretion and also the proliferative activity of cystic cholangiocytes. Alpini and coworkers have shown that cAMP stimulates proliferation in normal cholangiocytes via the PKA/Src/Raf/MEK/ERK1/2 cascade33. In cystic cholangiocytes, the proliferative response and ERK1/2 activation in response to cAMP is significantly higher, suggesting that cAMP levels are not the only determinant of ERK1/2 activation. In fact, polycystin may have additional effects directly mediated by the proteolytic cleavage and nuclear translocation of its carboxy-terminal tail to the nucleus.
Activation ERK1/2 has a number of effects, including stimulation of the mTOR pathway20. Both ERK1/2 and mTOR converge in stimulating cyclins and HIF1α. The list of HIF-1α-regulated genes is large, and includes genes coding for proteins involved in energy metabolism, erythropoiesis, and cell proliferation, in addition to VEGF. Mice deficient in PC2 show a severe liver phenotype, high proliferation rate of the cystic epithelium and high expression of VEGF and its receptor VEGFR-2. Expression of pERK1/2, p-mTOR and HIF1α, are also increased, suggesting that wild type PC2 acts as repressors of the cAMP/PKA/Raf/MEK/ERK/mTOR cascade20, 21. The observation that changes in Ca2+/cAMP signalling similar to the one described in PC-2 defective cells are common to cystic diseases characterized by different genetic defects and phenotypes suggests that PC2 is central to the pathogenesis of all PLD forms.
The pathophysiological relevance of this model is demonstrated by the reduction of cyst growth in vivo, after administration of SU5418 (inhibition of VEGFR2 signalling), or rapamycin (inhibition of mTOR and of VEGF production)20,21. Inhibition of cAMP production was also exploited as a therapeutic strategy. Somatostatin represses AC function through its receptor SSTR2, which is expressed in the liver only by cholangiocyte. Octreotide, given in vivo to PCK rats, reduced liver and kidney weight, hepatic and renal cyst volume and fibrosis, and diminished the rate of cell proliferation in hepatic and renal epithelia34. A recent randomized controlled double blind clinical trial revealed a 5% reduction in liver cyst volume in patients with symptomatic ADPKD/PLCD treated with the long-acting somatostatin analogue lanreotide35.
Several open questions remain. The mechanism leading to reduced cellular levels of Ca2+ are still obscure, and the impact of the lack of polycystins on ER Ca2+ homeostasis, and the role of AC6 need better understanding. In wild type animals, the result of increased cAMP-dependent proliferation is an expansion of the bile duct mass, rather than cystic transformation. Thus, the above working model addresses the mechanisms of progression of the established cysts, but does not explain how polycystins and fibrocystins actually interfere with the morphogenetic mechanisms in the biliary tree.
Acknowledgements
The authors wish to thank Carlo Spirli PhD for critically reading the manuscript
Grant Support: Supported by NIH DK079005, by Yale University Liver Center (NIH DK34989) and PKD Foundation to MS; DK51041 and DK54053 to SS.
Abbreviations
ADPKDautosomal dominant polycystic kidney disease
AKTv-akt murine thymoma viral oncogene homolog 1
ARPKDautosomal recessive polycystic kidney disease
CDCaroli disease
CFTRcystic fibrosis transmembrane conductance regulator
CHFcongenital hepatic fibrosis
DMPductal plate malformation
ECMextracellular matrix
EGFepidermal growth factor
ERendoplasmic reticulum
ERK1/2Extracellular-Regulated Kinase-1 and -2
HGFhepatocyte growth factor
HNF-1βhepatocyte nuclear factor 1 homeobox B
IGF-1Insulin-like growth factor 1
ILinterleukin
IP3Rinositol 1,4,5-trisphosphate receptor
MEKMitogen-activated protein kinase kinase
MMPmatrix metalloproteinase
mTORmammalian target of rapamycin
NHE3sodium-hydrogen exchanger 3
PC1polycystin-1;
PC2polycystin-2
PCLD“isolated” polycystic liver disease
PKDpolycystin kidney disease gene
PLDpolycystic liver disease
PRKCSHprotein kinase C substrate, 80 Kda protein
Rafproto-oncogene serine/threonine-protein kinase
RyRRyanodine receptor
SEC63SEC63 homolog (S. cerevisiae)
SSTR2Somatostatin receptor 2
STAT3Signal transducer and activator of transcription 3
STAT6signal transducer and activator of transcription 6, interleukin-4 induced
TGFβTransforming growth factor beta
Tie-2TEK tyrosine kinase
TRPP2transient receptor potential polycystic 2
TRVP4transient receptor potential vanilloid 4
VEGFvascular endothelial growth factor
VEGF-Rvascular endothelial growth factor receptor

Footnotes
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Both MS and SS declare that they have no conflict of interest with the content of this article.
1. Harris PC, Torres VE. Polycystic kidney disease. Annu.Rev.Med. 2009;60:321–337. [PMC free article] [PubMed]
2. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 2009;76:149–168. [PMC free article] [PubMed]
3. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology. 2004;127:1565–1577. [PubMed]
4. Nigg EA, Raff JW. Centrioles, centrosomes, and cilia in health and disease. Cell. 2009;139:663–678. [PubMed]
5. Drenth JP, Chrispijn M, Nagorney DM, Kamath PS, Torres VE. Medical and surgical treatment options for polycystic liver disease. Hepatology. 2010;52:2223–2230. [PubMed]
6. Lal M, Song X, Pluznick JL, et al. Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling. Hum.Mol.Genet. 2008;17:3105–3117. [PMC free article] [PubMed]
7. Low SH, Vasanth S, Larson CH, et al. Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev.Cell. 2006;10:57–69. [PubMed]
8. Distefano G, Boca M, Rowe I, et al. Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol.Cell.Biol. 2009;29:2359–2371. [PMC free article] [PubMed]
9. Anyatonwu GI, Estrada M, Tian X, Somlo S, Ehrlich BE. Regulation of ryanodine receptor-dependent calcium signaling by polycystin-2. Proc.Natl.Acad.Sci U S A. 2007;104:6454–6459. [PubMed]
10. Geng L, Boehmerle W, Maeda Y, et al. Syntaxin 5 regulates the endoplasmic reticulum channel-release properties of polycystin-2. Proc.Natl.Acad.Sci U.S.A. 2008;105:15920–15925. [PubMed]
11. Giamarchi A, Padilla F, Crest M, Honore E, Delmas P. TRPP2: Ca2+-permeable cation channel and more. Cell.Mol.Biol. 2006;52:105–114. [PubMed]
12. Kobori T, Smith GD, Sandford R, Edwardson JM. The transient receptor potential channels TRPP2 and TRPC1 form a heterotetramer with a 2:2 stoichiometry and an alternating subunit arrangement. J.Biol.Chem. 2009;284:35507–35513. [PubMed]
13. Li Y, Wright JM, Qian F, Germino GG, Guggino WB. Polycystin 2 interacts with type I inositol 1,4,5-trisphosphate receptor to modulate intracellular Ca2+ signaling. J.Biol.Chem. 2005;280:41298–41306. [PubMed]
14. Davila S, Furu L, Gharavi AG, et al. Mutations in SEC63 cause autosomal dominant polycystic liver disease. Nat.Genet. 2004;36:575–577. [PubMed]
15. Drenth JP, te Morsche RH, Smink R, Bonifacino JS, Jansen JB. Germline mutations in PRKCSH are associated with autosomal dominant polycystic liver disease. Nat.Genet. 2003;33:345–347. [PubMed]
16. Hiesberger T, Gourley E, Erickson A, et al. Proteolytic cleavage and nuclear translocation of fibrocystin is regulated by intracellular Ca2+ and activation of protein kinase C. J Biol Chem. 2006;281:34357–34364. [PubMed]
17. Kaimori JY, Nagasawa Y, Menezes LF, et al. Polyductin undergoes notch-like processing and regulated release from primary cilia. Hum.Mol.Genet. 2007;16:942–956. [PMC free article] [PubMed]
18. Mai W, Chen D, Ding T, et al. Inhibition of Pkhd1 impairs tubulomorphogenesis of cultured IMCD cells. Mol Biol Cell. 2005;16:4398–4409. [PMC free article] [PubMed]
19. Igarashi P, Shao X, McNally BT, Hiesberger T. Roles of HNF-1beta in kidney development and congenital cystic diseases. Kidney Int. 2005;68:1944–1947. [PubMed]
20. Spirli C, Okolicsanyi S, Fiorotto R, et al. Mammalian target of rapamycin regulates vascular endothelial growth factor-dependent liver cyst growth in polycystin-2-defective mice. Hepatology. 2010;51:1778–1788. [PMC free article] [PubMed]
21. Spirli C, Okolicsanyi S, Fiorotto R, et al. ERK1/2-dependent vascular endothelial growth factor signaling sustains cyst growth in polycystin-2 defective mice. Gastroenterology. 2010;138:360–371. [PMC free article] [PubMed]
22. Strazzabosco M, Fabris L. Functional anatomy of normal bile ducts. Anat Rec. 2008;291:653–660. [PubMed]
23. Masyuk AI, Masyuk TV, Splinter PL, et al. Cholangiocyte cilia detect changes in luminal fluid flow and transmit them into intracellular Ca2+ and cAMP signaling. Gastroenterology. 2006;131:911–920. [PMC free article] [PubMed]
24. Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangiopathies. J.Clin.Gastroenterol. 2005;39:S90–S102. [PubMed]
25. Strazzabosco M, Fiorotto R, Melero S, et al. Differentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation. Hepatology. 2009;50:244–252. [PMC free article] [PubMed]
26. Xu N, Glockner JF, Rossetti S, et al. Autosomal dominant polycystic kidney disease coexisting with cystic fibrosis. J Nephrol. 2006;19:529–534. [PubMed]
27. Patel V, Li L, Cobo-Stark P, et al. Acute kidney injury and aberrant planar cell polarity induce cyst formation in mice lacking renal cilia. Hum.Mol.Genet. 2008;17:1578–1590. [PMC free article] [PubMed]
28. Fabris L, Cadamuro M, Fiorotto R, et al. Effects of angiogenic factor overexpression by human and rodent cholangiocytes in polycystic liver diseases. Hepatology. 2006;43:1001–1012. [PubMed]
29. Nichols MT, Gidey E, Matzakos T, et al. Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. Hepatology. 2004;40:836–846. [PubMed]
30. Fabris L, Cadamuro M, Libbrecht L, et al. Epithelial expression of angiogenic growth factors modulate arterial vasculogenesis in human liver development. Hepatology. 2008;47:719–728. [PubMed]
31. Alvaro D, Onori P, Metalli VD, et al. Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology. 2002;36:297–304. [PubMed]
32. Gradilone SA, Masyuk AI, Splinter PL, et al. Cholangiocyte cilia express TRPV4 and detect changes in luminal tonicity inducing bicarbonate secretion. Proc.Natl.Acad.Sci.U.S.A. 2007;104:19138–19143. [PubMed]
33. Gaudio E, Barbaro B, Alvaro D, et al. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology. 2006;130:1270–1282. [PubMed]
34. Masyuk TV, Masyuk AI, Torres VE, Harris PC, Larusso NF. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology. 2007;132:1104–1116. [PubMed]
35. van Keimpema L, Nevens F, Vanslembrouck R, et al. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2009;137:1661–1668. e1–e2. [PubMed]